Document is current
Any future updates will be listed below
-
Authors
Enami, Miwa Sonoda
Hirata, Aya
Kuwabara, Kazuyo
Miyazaki, Junji
Kubota, Yoshimi
Nishida, Yoko
Kubo, Sachimi
Hirata, Takumi
Uchida, Tomoe
Kadota, Aya
Higashiyama, Aya
Sugiyama, Daisuke
Nishikawa, Tomofumi
Miyamatsu, Naomi
Miyamoto, Yoshihiro
Okamura, Tomonori
-
Funding
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science and Technology
a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science
Japan Agency for Medical Research and Development
Ministry of Health, Labour and Welfare
- License Information
-
More Information
Article History
Received: 30 June 2025
Accepted: 31 December 2025
First Online: 8 January 2026
Declarations
:
: The study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Pharmaceutical Clinical Research Review Committee (Ethics Committee) of the Institute of Biomedical Research and Innovation at the Kobe Biomedical Innovation Cluster (approval no. 10–20) and the Ethics Committee of Keio University School of Medicine (approval no. 20170142 and 20211116). All participants were provided with written and oral explanations and gave written informed consent prior to participation, ensuring voluntary involvement and data confidentiality.
: Not applicable.
: ME is currently affiliated with Pfizer Japan Inc. The authors declare no competing interests.
